This recorded session was talk about the latest Guidelines in management of Type 2 Diabetes and where the newer therapies such as SGLTL2 inhibitors and GLP1 Receptor agonists fit in.  

There has been a vast amount of positive clinical data in the last 6 years showing the newer therapies can provide cardiovascular benefit and improve prognosis.